Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1053/j.ajkd.2013.11.023 http://scihub22266oqcxt.onion/10.1053/j.ajkd.2013.11.023 24411715!4159074!24411715     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24411715&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24411715.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Am+J+Kidney+Dis 2014 ; 63 (4): 677-90 Nephropedia Template TP {{tp|p=24411715|t=2014. Lupus nephritis: the evolving role of novel therapeutics |pdf=|usr=}}{{24411715}} gab.com Text Lupus nephritis: the evolving role of novel therapeutics JO: Am J Kidney Dis http://www.kidney.de/pget.php?&tw=1&pmid=24411715 #FOAvip Immune complex accumulation in the kidney is the hallmark of lupus nephritis and triggers a series of events that result in kidney inflammation and injury. Cytotoxic agents and corticosteroids are standard of care for lupus nephritis treatment, but are associated with considerable morbidity and suboptimal outcomes. Recently, there has been interest in using novel biologic agents and small molecules to treat lupus nephritis. These therapies can be broadly categorized as anti-inflammatory (laquinamod, anti-tumor necrosis factor-like weak inducer of apotosis, anti-C5, and retinoids), antiautoimmunity (anti-CD20, anti-interferon alpha, and costimulatory blockers), or both (anti-interleukin 6 and proteasome inhibitors). Recent lupus nephritis clinical trials applied biologics or small molecules of any category to induction treatment, seeking short-term end points of complete renal response. These trials in general have not succeeded. When lupus nephritis comes to clinical attention during the inflammatory stage of the disease, the autoimmune stage leading to kidney inflammation will have been active for some time. The optimal approach for using novel therapies may be to initially target kidney inflammation to preserve renal parenchyma, followed by suppression of autoimmunity. In this review, we discuss novel lupus nephritis therapies and how they fit into a combinatorial treatment strategy based on the pathogenic stage. Twit Text FOAVip Lupus nephritis: the evolving role of novel therapeutics ????Am J Kidney Dis http://www.kidney.de/pget.php?&tw=1&pmid=24411715 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24411715 #FOAvip English Wikipedia <ref>{{Cite pmid|24411715}}</ref> Lupus nephritis: the evolving role of novel therapeutics #MMPMID24411715 Rovin BH; Parikh SV Am J Kidney Dis 2014[Apr]; 63 (4): 677-90 PMID24411715show ga Immune complex accumulation in the kidney is the hallmark of lupus nephritis and triggers a series of events that result in kidney inflammation and injury. Cytotoxic agents and corticosteroids are standard of care for lupus nephritis treatment, but are associated with considerable morbidity and suboptimal outcomes. Recently, there has been interest in using novel biologic agents and small molecules to treat lupus nephritis. These therapies can be broadly categorized as anti-inflammatory (laquinamod, anti-tumor necrosis factor-like weak inducer of apotosis, anti-C5, and retinoids), antiautoimmunity (anti-CD20, anti-interferon alpha, and costimulatory blockers), or both (anti-interleukin 6 and proteasome inhibitors). Recent lupus nephritis clinical trials applied biologics or small molecules of any category to induction treatment, seeking short-term end points of complete renal response. These trials in general have not succeeded. When lupus nephritis comes to clinical attention during the inflammatory stage of the disease, the autoimmune stage leading to kidney inflammation will have been active for some time. The optimal approach for using novel therapies may be to initially target kidney inflammation to preserve renal parenchyma, followed by suppression of autoimmunity. In this review, we discuss novel lupus nephritis therapies and how they fit into a combinatorial treatment strategy based on the pathogenic stage. |Abatacept[MESH] |Acute Kidney Injury/etiology/immunology[MESH] |Adolescent[MESH] |Algorithms[MESH] |Antibodies, Monoclonal, Humanized/therapeutic use[MESH] |Antibodies, Monoclonal, Murine-Derived/administration & dosage[MESH] |Apoptosis/immunology[MESH] |Autoantibodies/metabolism[MESH] |B-Lymphocytes/drug effects/immunology[MESH] |Cytokine TWEAK[MESH] |Drug Therapy, Combination[MESH] |Female[MESH] |Genetic Predisposition to Disease[MESH] |Humans[MESH] |Immunoconjugates/pharmacology/therapeutic use[MESH] |Immunosuppressive Agents/administration & dosage/pharmacology/*therapeutic use[MESH] |Interleukin-6/antagonists & inhibitors[MESH] |Lupus Erythematosus, Systemic/genetics[MESH] |Lupus Nephritis/complications/*drug therapy/immunology/pathology[MESH] |Quinolones/therapeutic use[MESH] |Remission Induction[MESH] |Rituximab[MESH]Lupus nephritis: the evolving role of novel therapeutics (epmc).pdf DeepDyve Pubget Overpricing